10

Loading video...

Lucy Notarantonio

By Lucy Notarantonio

Senior Reporter

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


A recent study has revealed that an aspirin a day may stop cancer from spreading.

In 2025, over 2 million new cancer cases are expected in the U.S., with more than 618,000 deaths—about 1,700 per day—according to the American Cancer Society.

The research, conducted by scientists at the University of Cambridge in England, discovered the common drug could reduce metastasis—the spread of cancer cells from the original tumor to other parts of the body—by stimulating the immune system.

Read More on Health

It is estimated that some 90 percent of cancer deaths occur after spreading to other parts of the body.

Professor Rahul Roychoudhuri, from the University of Cambridge, who led the study, told Newsweek: "I believe the appropriate message for cancer patients is one of cautious optimism balanced with medical guidance.

"Aspirin is indeed low-cost and widely available, but it's not without significant risks. Long-term aspirin use is associated with gastrointestinal toxicity including peptic ulceration and upper gastrointestinal bleeding.

"There is also an increased risk of hemorrhagic stroke, particularly in older individuals. The risk-benefit calculation varies substantially between individuals based on age, comorbidities, and concurrent medications."

A stock image of a man holding pill in one hand and glass of water. Scientists have uncovered the mechanism behind how aspirin could reduce the spread of cancer.

...

Roychoudhuri advises patients interested in aspirin therapy to discuss it with their oncologist or family practitioner, who can evaluate the potential benefits against these risks in their specific case.

Clinical trials are underway to determine how to use it safely and effectively to prevent cancer from spreading.

Studies of people with cancer have previously found that those taking daily low-dose aspirin have a reduction in the spread of some cancers, such as breast, bowel, and prostate cancers, leading to ongoing clinical trials. However, until now it wasn't known exactly how aspirin could prevent the spread.

The study, primarily funded by the Medical Research Council and published in Nature, was conducted using mice. The researchers screened 810 genes and found 15 that affected cancer metastasis. They discovered that mice lacking a gene that produces a protein called ARHGEF1 had less metastasis of various primary cancers to the lungs and liver.

They found that ARHGEF1 suppresses a type of immune cell known as the T cell that can recognize and kill metastatic cancer cells.

Scientists wanted to develop treatments based on this discovery, but first, they needed to figure out how to get drugs to target it. They followed signals inside the cell and found that a protein called ARHGEF1 gets activated when immune cells (T cells) come into contact with a clotting factor called thromboxane A2 (TXA2).

This was surprising because TXA2 is already well known—it plays a role in how aspirin works. TXA2 is made by platelets, the blood cells that help form clots to stop bleeding. While this is usually helpful, it can sometimes lead to heart attacks and strokes. Aspirin works by reducing TXA2, which is why it helps prevent these conditions.

The new research revealed that aspirin also helps stop cancer from spreading by lowering TXA2 levels. This frees up T cells, allowing them to fight cancer more effectively. In experiments with mice that had melanoma (a type of skin cancer), those given aspirin had fewer cases of cancer spread (metastases) compared to those that didn't.

The scientists found that this was due to aspirin reducing TXA2 and allowing T cells to do their job.

Dr. Jie Yang, who carried out the research at the University of Cambridge, said: "It was a eureka moment when we found TXA2 was the molecular signal that activates this suppressive effect on T cells.

"Before this, we had not been aware of the implication of our findings in understanding the anti-metastatic activity of aspirin. It was an entirely unexpected finding which sent us down quite a different path of enquiry than we had anticipated."

Newsweek has reached out to Dr. Jie Yang for comment via email.

Roychoudhuri said: "Despite advances in cancer treatment, many patients with early stage cancers receive treatments, such as surgical removal of the tumour, which have the potential to be curative, but later relapse due to the eventual growth of micrometastases—cancer cells that have seeded other parts of the body but remain in a latent state.

"Most immunotherapies are developed to treat patients with established metastatic cancer, but when cancer first spreads there's a unique therapeutic window of opportunity when cancer cells are particularly vulnerable to immune attack. We hope that therapies that target this window of vulnerability will have tremendous scope in preventing recurrence in patients with early cancer at risk of recurrence.

Yang added: "Aspirin, or other drugs that could target this pathway, have the potential to be less expensive than antibody-based therapies, and therefore more accessible globally."

In the future, the researchers plan to help translate their work into potential clinical practice by collaborating with Professor Ruth Langley of the MRC Clinical Trials Unit at University College London, who is leading the Add-Aspirin clinical trial to find out if aspirin can stop or delay early-stage cancers from coming back.

Professor Langley, who was not involved in this study, commented: "This is an important discovery. It will enable us to interpret the results of ongoing clinical trials and work out who is most likely to benefit from aspirin after a cancer diagnosis."

Do you have a tip on a health story that Newsweek should be covering? Do you have a question about cancer? Let us know via science@newsweek.com.

References

Yang, J., Yamashita-Kanemaru, Y., Morris, B. I., Contursi, A., Trajkovski, D., Xu, J., Patrascan, I., Benson, J., Evans, A. C., Conti, A. G., Al-Deka, A., Dahmani, L., Avdic-Belltheus, A., Zhang, B., Okkenhaug, H., Whiteside, S. K., Imianowski, C. J., Wesolowski, A. J., Webb, L. V., ... Roychoudhuri, R. (2025). Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity. Nature, 625(7862). https://doi.org/10.1038/s41586-025-08626-7

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines